E-Mail
WHO Benjamin Rome, MD, Instructor of Medicine at Harvard Medical School and researcher in the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital; corresponding author of a paper published in
WHAT When drug manufacturers raise the list price for brand-name prescription drugs, do patients out-of-pocket costs rise too? A new study published in
JAMA Network Open by Dr. Benjamin Rome and colleagues in the Brigham s Division of Pharmacoepidemiology and Pharmacoeconomics finds that more than half of patients may experience increases in out-of-pocket spending when drug prices increase.
Rome and co-authors studied 79 brand-name drugs and found that the list price charged by drug manufacturers increased 16.7 percent, the net price (after manufacturer rebates) by 5.4 percent, and average out-of-pocket costs by 3.5 percent from 2015 to 2017. Some commercially insured patients who
Date Time
Researchers Identify Potential Targets for Novel Treatments for Lung Cancer
Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease.
A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology in the laboratory of Daniel Tenen MD, at Beth Israel Deaconess Medical Center (BIDMC), evaluated a novel agent, PTC596, capable of decreasing tumor growth in preclinical studies performed on a mouse model of mutant K-RAS lung cancer. The research – performed in collaboration with the Cancer Science Institute of Singapore at the National University of Singapore (CSI NUS) – were published today in the journal Communications Biology. The findings, which represent a comprehensive snapshot of the tumor’s components, will facilitate the d